Sign up to save your podcasts
Or
Share Pharma and Biotech Daily: Biden's Prescription Drug Price Negotiation Expansion, Novo Nordisk's Obesity Candidate Success, GSK's Blenrep Progress, and More!
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Pharma and Biotech Daily: Biden's Prescription Drug Price Negotiation Expansion, Novo Nordisk's Obesity Candidate Success, GSK's Blenrep Progress, and More!
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.President Joe Biden has proposed expanding the Inflation Reduction Act to include an increase in the number of prescription drugs subject to price negotiations from 20 to 50 annually. This proposal comes ahead of his State of the Union address. Novo Nordisk has reported positive Phase I data for their next-generation obesity candidate, showing a 13.1% reduction in body weight with a favorable safety profile. GSK has also advanced Blenrep's potential comeback with a second Phase III win in second-line multiple myeloma. Additionally, cancer-focused Boundless Bio has filed for an IPO to fund the development of novel cancer therapies targeting extrachromosomal DNA. ITF is preparing for an FDA decision on expanding the DMD market, AstraZeneca is investing in the UK for vaccine manufacturing and R&D, and Gilead and Merus have signed a potential $1.5 billion deal for T-cell engagers. This update also includes job listings in the biopharma industry.
Support the Show.
View all episodes
By Pharma and BioTech News
3.5
1414 ratings
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.President Joe Biden has proposed expanding the Inflation Reduction Act to include an increase in the number of prescription drugs subject to price negotiations from 20 to 50 annually. This proposal comes ahead of his State of the Union address. Novo Nordisk has reported positive Phase I data for their next-generation obesity candidate, showing a 13.1% reduction in body weight with a favorable safety profile. GSK has also advanced Blenrep's potential comeback with a second Phase III win in second-line multiple myeloma. Additionally, cancer-focused Boundless Bio has filed for an IPO to fund the development of novel cancer therapies targeting extrachromosomal DNA. ITF is preparing for an FDA decision on expanding the DMD market, AstraZeneca is investing in the UK for vaccine manufacturing and R&D, and Gilead and Merus have signed a potential $1.5 billion deal for T-cell engagers. This update also includes job listings in the biopharma industry.
Support the Show.
More shows like Pharma and BioTech Daily
View all
WSJ Your Money Briefing
1,721 Listeners
WSJ What’s News
4,356 Listeners
The McKinsey Podcast
391 Listeners
WSJ Tech News Briefing
1,639 Listeners
HBR IdeaCast
176 Listeners
The Long Run with Luke Timmerman
123 Listeners
The Readout Loud
324 Listeners
Becker’s Healthcare Podcast
190 Listeners
Morning Brew Daily
3,002 Listeners
Inside Global Pharma
10 Listeners
Business Of Biotech
86 Listeners
BioCentury This Week
34 Listeners
Biotech Hangout
19 Listeners
The Top Line
14 Listeners
The AI Podcast
6 Listeners